MediciNova, Inc.

As of June 2, 2025, the market trend is mildly bearish, indicated by bearish momentum in the weekly MACD and daily moving averages, despite some mixed signals from the monthly MACD and KST suggesting cautious bullishness.

As of March 2022, the management team of MediciNova, Inc. includes Dr. Jeffrey Himawan (Independent Chairman), Dr. Yuichi Iwaki (President and CEO), Dr. Kazuko Matsuda (Chief Medical Officer), Ms. Carolyn Beaver (Director), and Mr. Hideki Nagao (Independent Director). They oversee the company's strategic direction and operations.

MediciNova, Inc. is a biopharmaceutical company developing small molecule therapeutics for serious diseases with unmet medical needs, classified as a micro-cap with a market cap of $61.80 million. As of March 2025, it reported a net profit loss of $3 million and has no dividend yield.

As of Jun 18, MediciNova, Inc. has a market capitalization of 61.80 million and reported net sales of 0.00 million with a net profit of -11.15 million for the latest four quarters. Shareholder's funds are at 52.50 million and total assets at 55.88 million as of Dec 24.